Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 75
Filtrar
1.
Infect Dis Ther ; 11(4): 1559-1574, 2022 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-35618953

RESUMO

INTRODUCTION: Acute lung injury and acute respiratory distress syndrome are common complications in patients with coronavirus disease 2019 (COVID-19). Poor outcomes in patients with COVID-19 are associated with cytokine release syndrome. Binding of interleukin-8 (CXCL8/IL-8) to its chemokine receptors, CXCR1/2, may mediate this inflammatory process. The aim of this clinical trial was to determine if CXCR1/2 blockade with reparixin can improve clinical outcomes in hospitalized patients with severe COVID-19 pneumonia. The dose and safety of reparixin have been investigated in clinical trials of patients with metastatic breast cancer. METHODS: This was a phase 2, open-label, multicenter, randomized study in hospitalized adult patients with severe COVID-19 pneumonia from May 5, 2020 until November 27, 2020. Patients were randomized 2:1 to receive 1200 mg reparixin orally three times daily or standard of care (SOC) for up to 21 days. The primary endpoint was defined as a composite of clinical events: use of supplemental oxygen, need for mechanical ventilation, intensive care unit admission, and/or use of rescue medication. RESULTS: Fifty-five patients were enrolled between reparixin (n = 36) and SOC (n = 19). The rate of clinical events was statistically significantly lower in the reparixin group compared with the SOC group (16.7% [95% CI 6.4-32.8%] vs. 42.1% [95% CI 20.3-66.5%], P = 0.02). The sensitivity analysis based on the Cox regression model provided an adjusted hazard ratio of 0.33 with statistical significance lower than 0.05 (95% CI 0.11-0.99; P = 0.047). Reparixin treatment appeared to be well tolerated. CONCLUSION: In patients with severe COVID-19, reparixin led to an improvement in clinical outcomes when compared with the SOC. A larger phase 3 clinical study is needed to confirm these results. TRIAL REGISTRATION: EudraCT identifier, 2020-001645-40; registered May 6, 2020 (retrospectively registered), and clinicaltrials.gov (NCT04794803) on March 8, 2021.

2.
Cell Death Dis ; 13(5): 498, 2022 05 25.
Artigo em Inglês | MEDLINE | ID: mdl-35614039

RESUMO

The new coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic, which so far has caused over 6 million deaths in 2 years, despite new vaccines and antiviral medications. Drug repurposing, an approach for the potential application of existing pharmaceutical products to new therapeutic indications, could be an effective strategy to obtain quick answers to medical emergencies. Following a virtual screening campaign on the most relevant viral proteins, we identified the drug raloxifene, a known Selective Estrogen Receptor Modulator (SERM), as a new potential agent to treat mild-to-moderate COVID-19 patients. In this paper we report a comprehensive pharmacological characterization of raloxifene in relevant in vitro models of COVID-19, specifically in Vero E6 and Calu-3 cell lines infected with SARS-CoV-2. A large panel of the most common SARS-CoV-2 variants isolated in Europe, United Kingdom, Brazil, South Africa and India was tested to demonstrate the drug's ability in contrasting the viral cytopathic effect (CPE). Literature data support a beneficial effect by raloxifene against the viral infection due to its ability to interact with viral proteins and activate protective estrogen receptor-mediated mechanisms in the host cells. Mechanistic studies here reported confirm the significant affinity of raloxifene for the Spike protein, as predicted by in silico studies, and show that the drug treatment does not directly affect Spike/ACE2 interaction or viral internalization in infected cell lines. Interestingly, raloxifene can counteract Spike-mediated ADAM17 activation in human pulmonary cells, thus providing new insights on its mechanism of action. A clinical study in mild to moderate COVID-19 patients (NCT05172050) has been recently completed. Our contribution to evaluate raloxifene results on SARS-CoV-2 variants, and the interpretation of the mechanisms of action will be key elements to better understand the trial results, and to design new clinical studies aiming to evaluate the potential development of raloxifene in this indication.


Assuntos
Tratamento Farmacológico da COVID-19 , SARS-CoV-2 , Antivirais/farmacologia , Antivirais/uso terapêutico , Humanos , Pandemias , Cloridrato de Raloxifeno/farmacologia , Cloridrato de Raloxifeno/uso terapêutico , Glicoproteína da Espícula de Coronavírus/metabolismo
3.
Cell Death Differ ; 29(1): 156-166, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-34404919

RESUMO

The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates strategies to identify prophylactic and therapeutic drug candidates to enter rapid clinical development. This is particularly true, given the uncertainty about the endurance of the immune memory induced by both previous infections or vaccines, and given the fact that the eradication of SARS-CoV-2 might be challenging to reach, given the attack rate of the virus, which would require unusually high protection by a vaccine. Here, we show how raloxifene, a selective estrogen receptor modulator with anti-inflammatory and antiviral properties, emerges as an attractive candidate entering clinical trials to test its efficacy in early-stage treatment COVID-19 patients.


Assuntos
Anti-Inflamatórios/uso terapêutico , Tratamento Farmacológico da COVID-19 , Reposicionamento de Medicamentos , Moduladores de Receptor Estrogênico/uso terapêutico , Cloridrato de Raloxifeno/uso terapêutico , Enzima de Conversão de Angiotensina 2/metabolismo , Antivirais/uso terapêutico , Estradiol/uso terapêutico , Estrogênios/metabolismo , Feminino , Humanos , Masculino , SARS-CoV-2/efeitos dos fármacos , Fatores Sexuais
5.
J Thorac Oncol ; 16(4): 546-571, 2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-33422679

RESUMO

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads mainly by means of aerosols (microdroplets) in enclosed environments, especially those in which temperature and humidity are regulated by means of air-conditioning. About 30% of individuals infected with SARS-CoV-2 develop coronavirus disease 2019 (COVID-19) disease. Among them, approximately 25% require hospitalization. In medicine, cases are identified as those who become ill. During this pandemic, cases have been identified as those with a positive SARS-CoV-2 polymerase chain reaction test, including approximately 70% who were asymptomatic-this has caused unnecessary anxiety. Individuals more than 65 years old, those affected by obesity, diabetes, asthma, or are immune-depressed owing to cancer and other conditions, are at a higher risk of hospitalization and of dying of COVID-19. Healthy individuals younger than 40 years very rarely die of COVID-19. Estimates of the COVID-19 mortality rate vary because the definition of COVID-19-related deaths varies. Belgium has the highest death rate at 154.9 per 100,000 persons, because it includes anyone who died with symptoms compatible with COVID-19, even those never tested for SARS-CoV-2. The United States includes all patients who died with a positive test, whether they died because of, or with, SARS-CoV-2. Countries that include only patients in which COVID-19 was the main cause of death, rather than a cofactor, have lower death rates. Numerous therapies are being developed, and rapid improvements are anticipated. Because of disinformation, only approximately 50% of the U.S. population plans to receive a COVID-19 vaccine. By sharing accurate information, physicians, health professionals, and scientists play a key role in addressing myths and anxiety, help public health officials enact measures to decrease infections, and provide the best care for those who become sick. In this article, we discuss these issues.


Assuntos
COVID-19 , Doenças Transmissíveis , Coronavirus , Neoplasias Pulmonares , Idoso , Vacinas contra COVID-19 , Humanos , SARS-CoV-2 , Estados Unidos
6.
Cell Death Dis ; 11(10): 867, 2020 Oct 16.
Artigo em Inglês | MEDLINE | ID: mdl-33067416

RESUMO

Author Francesca Pentimalli was incorrectly associated with Histopathological Unit, IRCCS-Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124 Bari, Italy. The author's actual affiliation is Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, I-80131 Napoli, Italy.

7.
Cell Death Dis ; 11(9): 748, 2020 09 14.
Artigo em Inglês | MEDLINE | ID: mdl-32929059

RESUMO

Malignant pleural mesothelioma (MPM) is an aggressive cancer, related to asbestos exposure, which has a dismal prognosis. MPM diagnosis is late and often challenging, suggesting the need to identify more reliable molecular biomarkers. Here, we set out to identify differentially expressed miRNAs in epithelioid, biphasic, and sarcomatoid MPMs versus normal mesothelium and explored specific miRNA contribution to mesothelial tumorigenesis. We screened an LNA™-based miRNA-microrray with 14 formalin-fixed paraffin-embedded (FFPE) MPMs and 6 normal controls. Through real-time qRT-PCR we extended the analysis of a miRNA subset and further investigated miR-320a role through state-of-the-art techniques. We identified 16 upregulated and 32 downregulated miRNAs in MPMs versus normal tissue, including the previously identified potential biomarkers miR-21, miR-126, miR-143, miR-145. We showed in an extended series that miR-145, miR-10b, and miR-320a levels can discriminate tumor versus controls with high specificity and sensitivity. We focused on miR-320a because other family members were found downregulated in MPMs. However, stable miR-320a ectopic expression induced higher proliferation and migration ability, whereas miR-320a silencing reduced these processes, not supporting a classic tumor-suppressor role in MPM cell lines. Among putative targets, we found that miR-320a binds the 3'-UTR of the immune inhibitory receptor ligand PDL1 and, consistently, miR-320a modulation affects PDL1 levels in MPM cells. Finally, we showed that p53 over-expression induces the upregulation of miR-320a, along with miR-200a and miR-34a, both known to target PDL1, and reduces PDL1 levels in MPM cells. Our data suggest that PDL1 expression might be due to a defective p53-regulated miRNA response, which could contribute to MPM immune evasion or tumorigenesis through tumor-intrinsic roles.


Assuntos
Antígeno B7-H1/genética , Antígeno B7-H1/metabolismo , Mesotelioma Maligno/metabolismo , MicroRNAs/metabolismo , Proteína Supressora de Tumor p53/metabolismo , Linhagem Celular Tumoral , Movimento Celular/fisiologia , Proliferação de Células/fisiologia , Regulação para Baixo , Células HEK293 , Humanos , Mesotelioma Maligno/genética , Mesotelioma Maligno/patologia , MicroRNAs/genética , Transfecção , Proteína Supressora de Tumor p53/genética
9.
Cell Death Dis ; 11(7): 516, 2020 07 08.
Artigo em Inglês | MEDLINE | ID: mdl-32641762

RESUMO

Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome caused by Coronavirus 2 (SARS-CoV-2). In the light of its rapid global spreading, on 11 March 2020, the World Health Organization has declared it a pandemic. Interestingly, the global spreading of the disease is not uniform, but has so far left some countries relatively less affected. The reason(s) for this anomalous behavior are not fully understood, but distinct hypotheses have been proposed. Here we discuss the plausibility of two of them: the universal vaccination with Bacillus Calmette-Guerin (BCG) and the widespread use of the antimalarial drug chloroquine (CQ). Both have been amply discussed in the recent literature with positive and negative conclusions: we felt that a comprehensive presentation of the data available on them would be useful. The analysis of data for countries with over 1000 reported COVID-19 cases has shown that the incidence and mortality were higher in countries in which BCG vaccination is either absent or has been discontinued, as compared with the countries with universal vaccination. We have performed a similar analysis of the data available for CQ, a widely used drug in the African continent and in other countries in which malaria is endemic; we discuss it here because CQ has been used as the drug to treat COVID-19 patients. Several African countries no longer recommend it officially for the fight against malaria, due to the development of resistance to Plasmodium, but its use across the continent is still diffuse. Taken together, the data in the literature have led to the suggestion of a possible inverse correlation between BCG immunization and COVID-19 disease incidence and severity.


Assuntos
Antivirais/uso terapêutico , Vacina BCG/uso terapêutico , Betacoronavirus/efeitos dos fármacos , Cloroquina/uso terapêutico , Infecções por Coronavirus/prevenção & controle , Pandemias/prevenção & controle , Pneumonia Viral/prevenção & controle , África/epidemiologia , COVID-19 , Infecções por Coronavirus/tratamento farmacológico , Infecções por Coronavirus/epidemiologia , Humanos , Incidência , Pneumonia Viral/tratamento farmacológico , Pneumonia Viral/epidemiologia , SARS-CoV-2 , Vacinação , Tratamento Farmacológico da COVID-19
13.
J Cell Physiol ; 235(3): 2139-2148, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-31392727

RESUMO

The development of specific and individualized training programs is a possible way to improve athletic performance and minimize injuries in professional athletes. The information regarding the sport's physical demands and the athletes' physical profile have been, so far, considered as exhaustive for the design of effective training programs. However, it is currently emerging that the genetic profile has to be also taken into consideration. By merging medical and genetic data, it is thus possible to identify the athlete's specific attitude to respond to training, diet, and physical stress. In this context, we performed a study in which 30 professional soccer players, subjected to standard sport medical evaluation and practices, were also screened for genetic polymorphism in five key genes (ACTN3, COL5A1, MCT1, VEGF, and HFE). This genetic analysis represents the central point of a multidisciplinary method that can be adopted by elite soccer teams to obtain an improvement in athletic performance and a concomitant reduction of injuries by tailoring training and nutritional programs. The genetic fingerprinting of single athletes led to the identification of two performance-enhancing polymorphisms (ACTN3 18705C>T, VEGF-634C>G) significantly enriched. Moreover, we derived a genetic model based on the gene set analyzed, which was tentatively used to reduce athletes' predisposition to injuries, by dictating a personalized nutrition and training program. The potential usefulness of this approach is concordant with data showing that this team has been classified as the healthiest and least injured team in Europe while covering the highest distance/match with the highest number of high-intensity actions/match.


Assuntos
Desempenho Atlético/fisiologia , Predisposição Genética para Doença/genética , Polimorfismo de Nucleotídeo Único/genética , Futebol/fisiologia , Ferimentos e Lesões/genética , Atletas , Estudos de Associação Genética/métodos , Genômica , Genótipo , Humanos , Masculino
14.
J Cell Physiol ; 235(6): 5213-5222, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-31838757

RESUMO

In Italy, in the eastern area of the Campania region, the illegal dumping and burning of waste have been documented, which could potentially affect the local population's health. In particular, toxic waste exposure has been suggested to associate with increased cancer development/mortality in these areas, although a causal link has not yet been established. In this pilot study, we evaluated blood levels of toxic heavy metals and persistent organic pollutants (POPs) in 95 patients with different cancer types residing in this area and in 27 healthy individuals. While we did not find any significant correlation between the blood levels of POPs and the provenance of the patients, we did observe high blood concentrations of heavy metals in some municipalities, including Giugliano, where many illegal waste disposal sites have previously been documented. Our results showed that patients with different cancer types from Giugliano had higher blood levels of heavy metals than healthy controls. Despite the obvious limitations of this exploratory study, our preliminary observations encourage further research assessing the possible association between exposure to hazardous waste, increased blood metals, and increased risk of cancer.


Assuntos
Detecção Precoce de Câncer , Metais Pesados/sangue , Neoplasias/sangue , Poluentes Orgânicos Persistentes/sangue , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Feminino , Humanos , Itália/epidemiologia , Masculino , Metais Pesados/toxicidade , Pessoa de Meia-Idade , Neoplasias/induzido quimicamente , Neoplasias/patologia , Poluentes Orgânicos Persistentes/toxicidade , Adulto Jovem
17.
Biochem Biophys Res Commun ; 502(2): 173-182, 2018 07 12.
Artigo em Inglês | MEDLINE | ID: mdl-29887124

RESUMO

Recently, the emergence of an important alien plant pathogen in Europe was evident when the Olive Quick Decline Syndrome (OQDS), a previously unknown disease causing rapid scorching and death of the trees, invested with particular virulence a substantial portion of the vast olive wood of Southern Italy (Salento, part of the Apulia region). Early evidence indicated a connection between the OQDS and the gram-negative bacterium Xylella fastidiosa. This bacterium can target several important crops, so that researchers from all over the world have investigated its association with host plants and vectors, the molecular biology of the infection mechanism, and the molecular reaction of the infected plants. Potentially resistant or tolerant cultivars and molecular targets which might be useful to control the infection have been identified. In vitro tests of compounds active against Xylella have also been performed. In this contribution, the literature and the available data will be reviewed to provide an up-to-date picture of the currently available knowledge on the role of Xylella in OQDS, and in diseases of other plants, with focus on the emerging threats to European farming.


Assuntos
Olea/microbiologia , Doenças das Plantas/microbiologia , Xylella/patogenicidade , Agricultura , Animais , Ecossistema , Europa (Continente) , Interações Hospedeiro-Patógeno , Insetos Vetores/microbiologia , Biologia Molecular , Doenças das Plantas/prevenção & controle , Xylella/genética , Xylella/isolamento & purificação
18.
Cell Death Dis ; 9(3): 400, 2018 03 14.
Artigo em Inglês | MEDLINE | ID: mdl-29540667

RESUMO

Images in scientific papers are used to support the experimental description and the discussion of the findings since several centuries. In the field of biomedical sciences, in particular, the use of images to depict laboratory results is widely diffused, at such a level that one would not err in saying that there is barely any experimental paper devoid of images to document the attained results. With the advent of software for digital image manipulation, however, even photographic reproductions of experimental results may be easily altered by researchers, leading to an increasingly high rate of scientific papers containing unreliable images. In this paper I introduce a software pipeline to detect some of the most diffuse misbehaviours, running two independent tests on a random set of papers and on the full publishing record of a single journal. The results obtained by these two tests support the feasibility of the software approach and imply an alarming level of image manipulation in the published record.


Assuntos
Publicações/estatística & dados numéricos , Automação , Pesquisa Biomédica , Processamento de Imagem Assistida por Computador/normas , Processamento de Imagem Assistida por Computador/estatística & dados numéricos , Publicação de Acesso Aberto/normas , Publicação de Acesso Aberto/estatística & dados numéricos , Publicações/normas , Software
19.
Anticancer Res ; 37(4): 1609-1615, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-28373421

RESUMO

Recent aggressive chemotherapeutic and combined treatments have resulted in increased survivorship for advanced stage breast cancer. In some patients, treatment produces an actual abatement of their cancer, while in others treatment mitigates the progression of cancer bringing those patients into palliative care where their chronic disease requires continuous management. There is also evidence that the majority of palliative-care cancer patients have a deteriorating quality of life that only precipitously declines in the final few weeks of life. The new paradigm of patient-centered care for palliative patients is resulting in a new model of treatment in which the self-efficacy seems to play an important role. The present study represents an extension of the role of self-efficacy for coping to palliative care. Using a stress-coping model, the primary aim of this study was to evaluate a process model, in which self-efficacy for coping with cancer is a moderator between stress and the quality of life in a sample of breast cancer patients in palliative care. The secondary aim was to validate a specific domain coping self-efficacy scale, the Cancer Behavior Inventory. The current study confirmed the role of self-efficacy for coping with cancer as moderator of the relationship between stress and quality of life of a sample of breast cancer patients in palliative care. In addition, this study confirmed the structure, reliability and validity of the scale.


Assuntos
Adaptação Psicológica , Neoplasias da Mama/psicologia , Cuidados Paliativos/psicologia , Qualidade de Vida , Estresse Psicológico/psicologia , Adulto , Feminino , Humanos , Prognóstico , Autoeficácia , Adulto Jovem
20.
Oncotarget ; 6(1): 221-33, 2015 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-25473895

RESUMO

Constitutively active receptor tyrosine kinases (RTKs) are known oncogenic drivers and provide valuable therapeutic targets in many cancer types. However, clinical efficacy of RTK inhibitors is limited by intrinsic and acquired resistance. To identify genes conferring resistance to inhibition of the MET RTK, we conducted a forward genetics screen in the GTL-16 gastric cancer cell line, carrying MET amplification and exquisitely sensitive to MET inhibition. Cells were transduced with three different retroviral cDNA expression libraries and selected for growth in the presence of the MET inhibitor PHA-665752. Selected cells displayed robust and reproducible enrichment of library-derived cDNAs encoding truncated forms of RAF1 and BRAF proteins, whose silencing reversed the resistant phenotype. Transduction of naïve GTL-16 cells with truncated, but not full length, RAF1 and BRAF conferred in vitro and in vivo resistance to MET inhibitors, which could be reversed by MEK inhibition. Induction of resistance by truncated RAFs was confirmed in other MET-addicted cell lines, and further extended to EGFR-addicted cells. These data show that truncated RAF1 and BRAF proteins, recently described as products of genomic rearrangements in gastric cancer and other malignancies, have the ability to render neoplastic cells resistant to RTK-targeted therapy.


Assuntos
Resistencia a Medicamentos Antineoplásicos , Regulação Neoplásica da Expressão Gênica , Proteínas Proto-Oncogênicas c-met/metabolismo , Neoplasias Gástricas/metabolismo , Quinases raf/metabolismo , Animais , Linhagem Celular Tumoral , Sobrevivência Celular , DNA Complementar/metabolismo , Receptores ErbB/metabolismo , Feminino , Biblioteca Gênica , Humanos , Indóis/química , Camundongos , Camundongos Nus , Transplante de Neoplasias , Fenótipo , Inibidores de Proteínas Quinases/química , Proteínas Proto-Oncogênicas B-raf/metabolismo , Receptores Proteína Tirosina Quinases/metabolismo , Sulfonas/química , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...